CONMED Corp. Stock
CONMED Corp. Stock
A loss of -1.160% shows a downward development for CONMED Corp..
Our community is currently high on CONMED Corp. with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 59 € shows a very positive potential of 72.51% compared to the current price of 34.2 € for CONMED Corp..
Pros and Cons of CONMED Corp. in the next few years
Pros
?
M***** P*******
?
B****
?
S********** s********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of CONMED Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| CONMED Corp. | -1.160% | -1.143% | -3.889% | -49.855% | -48.358% | -60.000% | -60.000% |
| Icu Medical Inc. | -0.790% | 4.132% | 7.692% | -17.647% | -14.286% | -15.436% | -19.745% |
| Bio-Rad Labs Inc. A | 2.320% | -1.282% | -2.820% | -19.465% | -16.619% | -33.696% | -45.209% |
| Neogen Corp. | 1.710% | 13.592% | 5.405% | -49.569% | -51.250% | - | - |
Comments
CONMED (NYSE:CNMD) had its price target lowered by analysts at Piper Sandler from $68.00 to $55.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CNMD provided by MarketBeat
CONMED Corporation (NYSE: CNMD) had its price target lowered by analysts at Piper Sandler from $80.00 to $68.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CNMD provided by MarketBeat
CONMED Co. (NYSE: CNMD) had its price target lowered by analysts at Needham & Company LLC from $91.00 to $61.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CNMD provided by MarketBeat